BPC-157 vs GHK-Cu

Both are sold as components of the same multi-peptide research blends, which is where this pairing usually comes up: someone reading a blend's label wants to know what each part of it is. They are different classes of molecule, described in separate literatures, and treated differently by regulators.

What this comparison cannot establish

No study on either research index places both compounds in the same model. The two columns are separate literatures set side by side, not a head-to-head trial, and nothing here supports a conclusion that one compound does more than the other.
A property appearing in both columns does not mean it was measured the same way. The two bodies of work differ in size, in study type, and in how much of each is independent of the parties selling the material.
Neither compound is an approved drug in the United States. Rows describing regulatory or pharmacopoeial status record how each is treated administratively. They are not findings about what either does.
GHK-Cu carries a cosmetic ingredient listing, and a cosmetic ingredient listing speaks to appearance only. Nothing in this comparison describes either compound as affecting the structure or function of the body.

Published properties

Only properties both compounds publish are listed. Every value carries the primary source it came from.

Property	BPC-157	GHK-Cu
Cas number	137525-51-0 source	89030-95-5 source
Unii	8ED8NXK95P source	6BJQ43T1I9 source
Molecular formula	C62H98N16O22 source	C14H22N6O4.Cu (equivalently C14H22CuN6O4) source
Molecular weight	1419.5 g/mol source	401.91 g/mol source
Appearance	White to off-white lyophilised powder, stated under FDA's physicochemical characterisation heading for BPC-157 (free base). FDA describes BPC-157 acetate separately as a white to off-white solid powder. source	Crystallised from aqueous copper(II) acetate with ethanol it forms dark purple-blue octahedral crystals; in column purification the complex is collected as the elution peak absorbing at 600 nm. Stated under the cosmetic safety review's Method of Manufacture heading for copper tripeptide-1, so it describes the copper complex rather than the uncomplexed peptide. The underlying source is Pickart and Lovejoy, Methods in Enzymology 1987. source
Solubility	Soluble in water at 5 mg/mL. PROVENANCE: FDA states this in its characterisation section for both the free base and the acetate, but footnotes it to supplier product pages rather than to a published measurement. Because the substance is water-soluble and would be solubilised before administration, FDA does not consider particle size a critical quality attribute for the solution dosage forms it reviewed. source	Highly hydrophilic. Octanol / phosphate-buffered-saline distribution coefficients (log D) measured between -2.38 and -2.49 across the pH range 4.5 to 7.4. source
Storage	READ THE PROVENANCE BEFORE USING THIS. FDA's evaluation reports that lyophilised BPC-157 (free base) is stable at room temperature for three weeks, that it is recommended to be held desiccated below -18 degrees C because exposure to moisture greatly decreases the long-term stability of lyophilised peptides, and that once reconstituted it is stable for two to three weeks at 4 degrees C and for three to four months at -20 degrees C. FDA's own footnotes attribute every one of those figures to supplier product pages, not to a published stability study, and FDA states the conclusion as what is "reported in the literature" rather than as an agency determination. No peer-reviewed forced-degradation or shelf-life study for BPC-157 was located. FDA separately warns that peptides such as this one are extremely sensitive to formulation, process and environmental conditions including pH, temperature, concentration and excipients, which may lead to aggregation and degradation and to loss of biological activity, and that significant amounts of aggregates can form during storage. source	This is an accelerated stability finding, not a handling instruction. Under forced-degradation testing the complex remained stable in water and in pH 4.5 to 7.4 buffers held at 60 degrees C for at least two weeks, while basic and oxidative stressors, and to a lesser extent acidic stress, caused hydrolytic cleavage with first-order degradation profiles. A 60 degrees C challenge is a stress condition used to measure degradation kinetics; it is not a holding temperature, and the published literature does not establish one. source

What the research does not show

There is no published, adequately reported, randomised controlled trial of BPC-157 in people for any condition. The single randomised comparison that exists was published only as a conference abstract, and FDA states the data presented there are inadequate to support either efficacy or safety.
FDA's regulatory evaluation found only five clinical studies of BPC-157 in the entire published medical literature. Two of them are meeting abstracts rather than full papers. FDA describes the set as short in duration, small in sample size, exploratory in the doses used, and limited in the safety information the authors provided, and notes that safety monitoring is unclear for most of them. source
An independent systematic review of the orthopaedic literature screened 544 articles published between 1993 and 2024 and included 36 studies, of which 35 were preclinical and 1 was clinical. Its authors classify the body of work as level IV and level V evidence and state plainly that no clinical safety data were found. source
Route of administration in the published human studies does not match how the substance is actually supplied and used. FDA states it identified no study that gave BPC-157 to humans by the oral, subcutaneous, nasal or transdermal route. The two human studies FDA identified in which the substance was given repeatedly both used a rectal enema, a route almost nobody buying this compound uses.
The same gap exists in the animal safety work. FDA states that neither the nominators submitted, nor did FDA identify, nonclinical pharmacokinetic, acute toxicity, repeat-dose toxicity or developmental toxicity studies by any of the oral, rectal, transdermal, subcutaneous or nasal routes. The available animal toxicology used the intramuscular route, and because the absolute bioavailability of the other routes in rats and dogs is unknown, FDA states the intramuscular no-observed- adverse-effect levels cannot be used to estimate levels for those routes. source
The animal pharmacology does not establish a dose-response relationship. Across the rodent studies FDA reviewed, doses separated by three orders of magnitude (nanograms per kilogram versus micrograms per kilogram) produced effects of the same magnitude, so no dose-response could be established. FDA states the molecular targets of BPC-157 have not been identified and its mechanism of action remains poorly understood, which makes the biological plausibility of the reported effects difficult to assess. source
The 28-day animal toxicology carries unresolved signals rather than a clean result. FDA summarises the repeat-dose intramuscular studies in rats and dogs as showing clinically relevant safety signals including shortened and prolonged activated partial thromboplastin time, suggestive of altered clotting properties, and liver-associated signals comprising raised serum ALT, glucose and triglyceride levels. FDA states longer repeat-dose studies were unavailable to show whether those findings reproduce or whether further signals emerge, and that no carcinogenicity study exists. source
The published human studies that report favourable outcomes are uncontrolled and rely on self-report. The interstitial cystitis study cited here enrolled 12 women at a single private clinic, had one arm and no control group or blinding, and measured outcome with a self-rated Global Response Assessment questionnaire. The knee-pain report is a retrospective chart review in which some participants received BPC-157 combined with a second peptide, so nothing in it can be attributed to BPC-157 alone. source
A registered phase 1 study in healthy volunteers (NCT02637284) was started in 2015 and its results were never posted; FDA searched and was unable to find an associated published study. An independent review records that the researchers cancelled submission of the results in 2016. The trials that would characterise this substance in people were begun and then not reported. source
The evidence base is concentrated in a very small number of authors. A news investigation quotes a review team's count that the vast majority of the roughly 200 BPC-157 studies listed on PubMed include either Predrag Sikiric or Sven Seiwerth, both of the University of Zagreb, as a main author. That is a reported count from journalism rather than a published bibliometric analysis, and is recorded here as such. What can be checked directly is that the originating 1993 paper came from that same department, and that the reference list of FDA's own evaluation is dominated by papers from it. source
Nobody has measured what BPC-157 does in a person's bloodstream. FDA states there is no information with which to assess its human pharmacokinetics. The half-life, bioavailability and excretion figures on this page are from rats and dogs, and the route that produced them is not a route anyone has studied in people.
FDA considers the substance itself poorly characterised. Its evaluation concludes that both BPC-157 (free base) and BPC-157 acetate are "not well-characterized from the physical and chemical characterization perspective", citing naming conventions that do not follow USAN, INN or IUPAC standards, and missing or inadequate data on peptide-related impurities and aggregates, microbial quality, bacterial endotoxins and particle size. FDA notes that inconsistent naming is itself a safety risk because a patient may receive a different substance from the one intended. source
Commercial certificates of analysis for this substance generally report purity and nothing else. FDA reviewed the certificates supplied with both nominations and searched the literature for others, and found that most contain only purity testing results, with no impurity limits or results that would demonstrate control of the impurity profile, and no bioburden or bacterial endotoxin testing. FDA states that because of this it cannot rule out the potential for immunogenicity from those impurities and from peptide-related aggregates. source
The storage and solubility figures published on this site, and on every other site that carries them, trace back through FDA's evaluation to supplier product pages rather than to a published stability study. They are recorded here because FDA recorded them, with that provenance stated. No peer-reviewed shelf-life determination for this compound was located.
Much of the literature does not say which substance it studied. FDA notes repeatedly that published articles do not clearly identify whether the BPC-157 used was the free base or the acetate salt, and that it is often unclear whether a product described in a source was compounded at all. Findings reported for "BPC-157" therefore cannot always be assigned to a specific substance.
Adverse events reported to FDA exist but cannot be attributed. Every case FDA retrieved was confounded — by a second peptide given at the same time, by missing information about duration and concomitant medicines, or by use within a multi-ingredient product. Absence of a clean signal in a database this sparse is not evidence of safety.
The published research does not establish a dose, a route, a schedule, a duration, or a formulation for any use in a person, and it does not establish what happens with long-term use, because no long-term human study has been published.

What the research does not show about GHK-Cu

No large, independent, placebo-controlled trial has measured what GHK-Cu does to the appearance of human facial skin. The human work cited here is small, or applies formulations containing several active ingredients at once.
The human wrinkle trials reported in the cosmetic safety review were conducted on palmitoyl tripeptide-1, a different, fatty-acylated ingredient. They are not measurements of GHK-Cu, and nothing in them transfers to it.
In the one randomised human comparison published on CO2 laser-resurfaced skin, blinded evaluators and computer image analysis found no significant difference between the GHK-Cu regimen and the control regimen for redness, wrinkles, or overall skin quality. Only the patients' own satisfaction ratings differed.
The other published human report on facial appearance is a single-patient case in which copper-GHK was delivered together with four other actives by a resurfacing device, so nothing in it can be attributed to copper-GHK on its own.
The mechanistic literature cited here is cell-culture or rodent work rather than human skin. It describes what the molecule does to cells in a dish or to a rat, not what a cosmetic does on a face.
Review articles summarise and interpret existing work; they do not generate new evidence. Several values on this site are drawn from a cosmetic safety review or a narrative review rather than from the primary study behind them.
The human skin-permeation data cited here come from in vitro diffusion cells using excised skin under infinite-dose conditions. That does not establish how much copper crosses intact living skin from a normal cosmetic application.
The purity figure carried in the cosmetic safety review describes tripeptide-1 (GHK), the uncomplexed peptide GHK-Cu is made from, not GHK-Cu itself; that review's Composition/Impurities section carries no entry for copper tripeptide-1 at all. See the starting material purity entry, which sets out the discrepancy in full. The literature reviewed here therefore reports no purity figure for commercial GHK-Cu, and none for any individual supplier or lot, which is what a lot-specific certificate of analysis is for.
The expert-panel safety conclusion for copper tripeptide-1 is stated for the present practices of use and concentration described in that review. It does not extend to concentrations outside the ones surveyed there.
The published research does not establish an optimal topical concentration, vehicle, or frequency for appearance outcomes in people.
Published work does not establish how long any change in the appearance of skin persists once use stops, nor whether outcomes differ by skin type, age, or sex.

BPC-157 monograph · Research index · Reading a certificate of analysis